Clinical Data Regenxbio’s Duchenne gene therapy clears phase 3 hurdle PharmaphorumRegenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche's Elevidys.Gene Therapy PlatformRead full story pharminent May 14, 2026 (Last updated: May 14, 2026) Pharmaphorum Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche’s Elevidys. Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA hands BeOne, Taiho approvals for blood cancersNext: Degron adds $40M to series A, supporting immunology plans for molecular glue platform Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
